CAL-101 induces selective cytotoxicity in CLL cells independent of IgV_H mutational status or interphase cytogenetics. (A) CD19⁺ cells from patients with CLL (n = 16) were incubated with or without CAL-101 (0.01-100μM) for 48 hours. Viability was determined by MTT assay and was calculated relative to time-matched untreated controls. (B) CD19⁺ cells from patients with CLL (n = 40) were incubated with or without CAL-101 (0.1-10μM) for 48 hours. Viability was determined by annexin/PI flow cytometry. (C) CD19⁺ cells from patients with CLL (n = 40) were incubated with or without 10μM CAL-101 for 12 to 96 hours. Horizontal lines represent the mean. (D) CD19⁺ cells from patients with CLL (n = 40; 10 per group) were incubated with or without 10μM CAL-101 for 48 hours. Cytogenetics was determined independently of our laboratory. (E) CD19⁺ cells from patients with CLL (n = 30; 15 per group) were incubated with or without 10μM CAL-101 for 48 hours. Mutational status was determined independently of our laboratory. Error bars represent the SD from the mean. (F) CD19⁺ cells from CLL patient cells (n = 40) and CD19⁺ cells from normal B cells (n = 9) were incubated with 10μM CAL-101 for 48 hours. (B-F) Viability was determined by annexin/PI flow cytometry and was calculated relative to time-matched untreated controls. Horizontal lines represent the mean.